• 1
    Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2012; 8: 3442.
  • 2
    Valderhaug TG, Hjelmesaeth J, Hartmann A, et al. The association of early post-transplant glucose levels with long-term mortality. Diabetologia 2011; 54: 13411349.
  • 3
    Chakkera HA, Knowler WC, Devarapalli Y, et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010; 5: 16691675.
  • 4
    Burroughs TE, Swindle J, Takemoto S, et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007; 83: 10271034.
  • 5
    Hecking M, Werzowa J, Haidinger M, et al. Novel views on new-onset diabetes after transplantation: Development, prevention and treatment. Nephrol Dial Transplant 2013; 28: 550566.
  • 6
    Davidson JA, Wilkinson A. New-onset diabetes after transplantation 2003 International Consensus Guidelines: An endocrinologist's view. Diabetes Care 2004; 27: 805812.
  • 7
    Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care 2013; 36: 27632771.
  • 8
    Zelle DM, Corpeleijn E, Deinum J, et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care 2013; 36: 19261932.
  • 9
    Sharif A, de Vries AP, Porrini E, Hecking M, Saemann M. Clinical trials for treatment of NODAT: Time to collaborate. Transplantation 2012; 94: e23e24; author reply e24–e25.
  • 10
    Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739749.
  • 11
    Werzowa J, Hecking M, Haidinger M, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: A randomized, placebo-controlled clinical trial. Transplantation 2013; 95: 456462.
  • 12
    Sharif A. Metformin for patients with diabetes and concomitant renal restrictions-is there an evidence base? QJM 2013; 106: 291294.
  • 13
    Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: A meta-analysis. Oncologist 2013; 18: 148156.
  • 14
    Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis. CMAJ 2012; 184: E675E683.
  • 15
    Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: A retrospective cohort study. Diabetes Care 2003; 26: 29832989.
  • 16
    Murphy CE, Rodgers PT. Effects of thiazolidinediones on bone loss and fracture. Ann Pharmacother 2007; 41: 20142018.
  • 17
    Saemann MD, Krebs M. Thiazolidinediones in the treatment of patients with post-transplant-hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT)—A new therapeutic option? Wien Klin Wochenschr 2010; 122: 198202.
  • 18
    Shin MS, Yu JH, Jung CH, et al. The duration of sulfonylurea treatment is associated with beta-cell dysfunction in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2012; 14: 10331042.
  • 19
    Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501506.
  • 20
    Krepinsky J, Ingram AJ, Clase CM. Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 2000; 35: 500505.
  • 21
    Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2008; CD006739.
  • 22
    Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007; 28: 187218.
  • 23
    Ávila Dde L, Araújo GR, Silva M, et al. Vildagliptin ameliorates oxidative stress and pancreatic beta cell destruction in type 1 diabetic rats. Arch Med Res 2013; 44: 194202.
  • 24
    Jelsing J, Vrang N, van Witteloostuijn SB, Mark M, Klein T. The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice. J Endocrinol 2012; 214: 381387.
  • 25
    Poucher SM, Cheetham S, Francis J, Zinker B, Kirby M, Vickers SP. Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic beta-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes Obes Metab 2012; 14: 918926.
  • 26
    Takeda Y, Fujita Y, Honjo J, et al. Reduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in mice. Diabetologia 2012; 55: 404412.
  • 27
    Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10: 7384.
  • 28
    Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567575.
  • 29
    Ahren B, Foley JE, Ferrannini E, et al. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2010; 33: 730732.
  • 30
    Zhao R, Fuentes-Mattei E, Velazquez-Torres G, et al. Exenatide improves glucocorticoid-induced glucose intolerance in mice. Diabetes Metab Syndr Obes 2011; 4: 6165.
  • 31
    Ranta F, Avram D, Berchtold S, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes 2006; 55: 13801390.
  • 32
    Goke B, Hershon K, Kerr D, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: Comparison with metformin. Horm Metab Res 2008; 40: 892895.
  • 33
    Pi-Sunyer FX, Schweizer A, Mills D, Dejager S. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res Clin Pract 2007; 76: 132138.
  • 34
    Retnakaran R. Does addition of vildagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2007; 3: 572573.
  • 35
    Rosenstock J, Fitchet M. Vildagliptin: Clinical trials programme in monotherapy and combination therapy for type 2 diabetes. Int J Clin Pract Suppl 2008; (159): 1523.
  • 36
    Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013; 36: 10671073.
  • 37
    Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W. Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: A prospective 24-week randomized placebo-controlled trial. Diabetes Obes Metab 2011; 13: 947954.
  • 38
    Kothny W, Shao Q, Groop PH, Lukashevich V. One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes Metab 2012; 14: 10321039.
  • 39
    Ito M, Abe M, Okada K, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr J 2011; 58: 979987.
  • 40
    Valdes S, Botas P, Delgado E, Alvarez F, Cadorniga FD. Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias Study. Metabolism 2008; 57: 399403.
  • 41
    Haidinger M, Werzowa J, Voigt HC, et al. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 2010; 11: 91.
  • 42
    Bantle JP, Wylie-Rosett J, Albright AL, et al. Nutrition recommendations and interventions for diabetes: A position statement of the American Diabetes Association. Diabetes Care 2008; 31 (Suppl 1): S61S78.
  • 43
    Pacini G, Mari A. Methods for clinical assessment of insulin sensitivity and beta-cell function. Best Pract Res Clin Endocrinol Metab 2003; 17: 305322.
  • 44
    Ahren B, Pacini G, Tura A, Foley JE, Schweizer A. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm Metab Res 2007; 39: 826829.
  • 45
    Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for new-onset diabetes after kidney transplantation: Limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation 2013; 96: 726731.
  • 46
    Hamamoto S, Kanda Y, Shimoda M, et al. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes Metab 2013; 15: 153163.
  • 47
    Omar BA, Vikman J, Winzell MS, et al. Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model. Diabetologia 2013; 56: 17521760.
  • 48
    Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92: e56e57.
  • 49
    Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type 2 diabetes. Curr Drug Saf 2011; 6: 304309.
  • 50
    Theiss HD, Gross L, Vallaster M, et al. Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. Int J Cardiol 2013; 168: 33593369.
  • 51
    Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150156.
  • 52
    Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013; 62: 25952604.
  • 53
    Drucker DJ, Sherman SI, Bergenstal RM, Buse JB. The safety of incretin-based therapies—review of the scientific evidence. J Clin Endocrinol Metab 2011; 96: 20272031.
  • 54
    Didsbury M, McGee RG, Tong A, et al. Exercise training in solid organ transplant recipients: A systematic review and meta-analysis. Transplantation 2013; 95: 679687.
  • 55
    Romano G, Simonella R, Falleti E, et al. Physical training effects in renal transplant recipients. Clin Transplant 2010; 24: 510514.
  • 56
    Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353358.
  • 57
    Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation 2006; 82: 16671672.